“this is roughly a $4 billion market; with improved treatments it could grow significantly, potentially doubling to $8 billion to $10 billion by the mid-2030s.”

In context

“Adam Lenkowsky (Chief Commercialization Officer): Yes. Admilparant has the potential to play a meaningful role in both IPF and PPF with improved efficacy and tolerability. There is significant unmet need for therapies that slow or halt disease progression while being well tolerated. Gastrointestinal tolerability is a significant challenge with current agents; 50% to 60% of IPF patients stop their medications by 12 months with existing standard of care. Recent launches validate the market and show an opportunity for new, better tolerated treatments to gain significant share. We're already seeing a large second-line add-on and switch market emerge. JASCAYD, for instance, sees over 50% of starts coming after generics. Today this is roughly a $4 billion market; with improved treatments it could grow significantly, potentially doubling to $8 billion to $10 billion by the mid-2030s. We believe admilparant has the potential to be foundational as a first branded option with the versatility to be used in combination.”